Lilly
3Q Revenues: $11.4 billion (+20%) 
3Q Earnings: $970.3 million (loss of $57.4 million 3Q23) 
YTD Revenues: $31.5 billion (+27%)
YTD Earnings: $6.2 billion (+103%)
Comments: Mounjaro sales were $3.1 billion in the quarter, up from $1.4 billion 3Q23. Verzenio sales were up 32% to $1.37 billion. Zepbound sales were $1.26 billion in the quarter. Trulicity sales were down 22% in the quarter to $1.3 billion. 
 
Revenue in the U.S. increased 46% to $7.8 billion, driven by a 35% increase in volume and an 11% increase in realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro, partially offset by declines in Trulicity. 
 
Revenue outside the U.S. decreased 12% to $3.63 billion driven by the sale of rights for the olanzapine portfolio in 3Q23. Excluding the olanzapine portfolio, revenue and volume outside the U.S. increased 33% and 36%, respectively, primarily driven by Mounjaro and Verzenio.
Approvals in the quarter included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer’s disease.
 
3Q23 results include $2.98 billion charges primarily related to the acquisitions of DICE Therapeutics, Inc., Versanis Bio, Inc. and Emergence Therapeutics AG.